TOP TEN perturbations for 1553521_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553521_at
Selected probe(set): 1553521_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553521_at (1553521_at) across 6672 perturbations tested by GENEVESTIGATOR:

PMA study 6 (500ng/ml) / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):1.9222741
Number of Samples:3 / 17
Experimental PMA study 6 (500ng/ml)
Bronchial epithelial cells (NHBE) treated with tetradecanoylphorbol acetate (500ng/ml; vendor: Sigma / catalog number: P1585 / catalog name: Phorbol 12-myristate 13-acetate [16561-29-8]) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:---
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.3149791
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.2936506
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.1887116
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

CH5183284 study 1 (MFE-280) / vehicle (DMSO) treated MFE-280 cell sample

Relative Expression (log2-ratio):-1.1861277
Number of Samples:2 / 2
Experimental CH5183284 study 1 (MFE-280)
Human endometrial cell line MFE-280 treated with 1 uM of FGFR inhibitor CH5183284 for 24 hours. ATC code:---
Control vehicle (DMSO) treated MFE-280 cell sample
Human endometrial cell line MFE-280 treated with 0.1% DMSO for 24 hours.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.1492791
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.1249685
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

formaldehyde study 3 (4500ug/ml) / vehicle (EtOH) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):1.0328302
Number of Samples:3 / 3
Experimental formaldehyde study 3 (4500ug/ml)
Bronchial epithelial cells (NHBE) treated with 4500 ug/ml formaldehyde (within range of concentrations reported to induce toxicity in lung epithelial cells and other cell types) for 24 hours. NHBE cells were derived from a 60 year old male non-smoker. ATC code:---
Control vehicle (EtOH) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (ethanol) at a final concentration of 2% v/v (concentration that ensures >80% cell viability after 24 hours of exposure) for 24 hours. NHBE cells were derived from a 60 year old male non-smoker.

endometriosis study 5 (eutopic endometrium; secretory MCP) / endometriosis study 5 (eutopic endometrium; proliferative MCP)

Relative Expression (log2-ratio):-1.016509
Number of Samples:9 / 8
Experimental endometriosis study 5 (eutopic endometrium; secretory MCP)
Eutopic endometrial tissue samples collected from women with endometriosis in the secretory menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined based on combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, the knowledge of the patient’s last menstrual cycle, and analysis of specific histological criteria to identify menstrual cycle phases.
Control endometriosis study 5 (eutopic endometrium; proliferative MCP)
Eutopic endometrial tissue samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, the knowledge of the patient’s last menstrual cycle, and analysis of specific histological criteria to identify menstrual cycle phases.

endometriosis study 5 (endo. lesion; proliferative MCP) / endometriosis study 5 (eutopic endometrium; proliferative MCP)

Relative Expression (log2-ratio):-0.9108639
Number of Samples:8 / 8
Experimental endometriosis study 5 (endo. lesion; proliferative MCP)
Peritoneal endometriosis lesion samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, and the knowledge of the patient’s last menstrual cycle.
Control endometriosis study 5 (eutopic endometrium; proliferative MCP)
Eutopic endometrial tissue samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, the knowledge of the patient’s last menstrual cycle, and analysis of specific histological criteria to identify menstrual cycle phases.

Organism: Homo sapiens
Gene: 1553521_at
Selected probe(set): 1553521_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553521_at (1553521_at) across 6672 perturbations tested by GENEVESTIGATOR:

PMA study 6 (500ng/ml) / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):1.9222741
Number of Samples:3 / 17
Experimental PMA study 6 (500ng/ml)
Bronchial epithelial cells (NHBE) treated with tetradecanoylphorbol acetate (500ng/ml; vendor: Sigma / catalog number: P1585 / catalog name: Phorbol 12-myristate 13-acetate [16561-29-8]) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:---
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.3149791
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.2936506
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.1887116
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

CH5183284 study 1 (MFE-280) / vehicle (DMSO) treated MFE-280 cell sample

Relative Expression (log2-ratio):-1.1861277
Number of Samples:2 / 2
Experimental CH5183284 study 1 (MFE-280)
Human endometrial cell line MFE-280 treated with 1 uM of FGFR inhibitor CH5183284 for 24 hours. ATC code:---
Control vehicle (DMSO) treated MFE-280 cell sample
Human endometrial cell line MFE-280 treated with 0.1% DMSO for 24 hours.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.1492791
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.1249685
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

formaldehyde study 3 (4500ug/ml) / vehicle (EtOH) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):1.0328302
Number of Samples:3 / 3
Experimental formaldehyde study 3 (4500ug/ml)
Bronchial epithelial cells (NHBE) treated with 4500 ug/ml formaldehyde (within range of concentrations reported to induce toxicity in lung epithelial cells and other cell types) for 24 hours. NHBE cells were derived from a 60 year old male non-smoker. ATC code:---
Control vehicle (EtOH) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (ethanol) at a final concentration of 2% v/v (concentration that ensures >80% cell viability after 24 hours of exposure) for 24 hours. NHBE cells were derived from a 60 year old male non-smoker.

endometriosis study 5 (eutopic endometrium; secretory MCP) / endometriosis study 5 (eutopic endometrium; proliferative MCP)

Relative Expression (log2-ratio):-1.016509
Number of Samples:9 / 8
Experimental endometriosis study 5 (eutopic endometrium; secretory MCP)
Eutopic endometrial tissue samples collected from women with endometriosis in the secretory menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined based on combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, the knowledge of the patient’s last menstrual cycle, and analysis of specific histological criteria to identify menstrual cycle phases.
Control endometriosis study 5 (eutopic endometrium; proliferative MCP)
Eutopic endometrial tissue samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, the knowledge of the patient’s last menstrual cycle, and analysis of specific histological criteria to identify menstrual cycle phases.

endometriosis study 5 (endo. lesion; proliferative MCP) / endometriosis study 5 (eutopic endometrium; proliferative MCP)

Relative Expression (log2-ratio):-0.9108639
Number of Samples:8 / 8
Experimental endometriosis study 5 (endo. lesion; proliferative MCP)
Peritoneal endometriosis lesion samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, and the knowledge of the patient’s last menstrual cycle.
Control endometriosis study 5 (eutopic endometrium; proliferative MCP)
Eutopic endometrial tissue samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, the knowledge of the patient’s last menstrual cycle, and analysis of specific histological criteria to identify menstrual cycle phases.